Mission aligned markets organize hypotheses by disease area and biological mechanism. Each mission maintains its own index score, ranked portfolio, and funding pool. A hypothesis can belong to multiple missions.
Mission Index Scores aggregate the quality of each mission's hypothesis portfolio. Higher scores indicate stronger evidence, more feasible interventions, and greater therapeutic potential.
Cross-Mission Hypotheses connect disease areas. A single hypothesis targeting lysosomal pathways may simultaneously support Alzheimer's, Parkinson's, and ALS missions—demonstrating mechanism convergence across neurodegenerative diseases.
Dynamic Rebalancing: As new evidence emerges from debates, papers, and knowledge gap investigations, the system automatically re-scores hypotheses and updates mission rankings. Missions with declining evidence lose index points; missions with strengthening portfolios rise.
All neurodegenerative disease hypotheses
GBA, LRRK2 lysosomal, TFEB, and autophagy pathway hypotheses
Amyloid, tau, neuroinflammation, and synaptic hypotheses for AD
SOD1, C9orf72, TDP-43, and motor neuron degeneration hypotheses
Cross-disease microglial, astrocyte, and immune hypotheses
Alpha-synuclein, dopaminergic, GBA, and LRRK2 hypotheses for PD
Immune cell activation, TREM2 signaling, and neuroinflammation